$1.68
+0.03 (+1.82%)
Open$1.65
Previous Close$1.65
Day High$1.78
Day Low$1.65
52W High$12.90
52W Low$1.06
Volume—
Avg Volume106.0K
Market Cap11.62M
P/E Ratio—
EPS$-5.13
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,636.9% upside
Current
$1.68
$1.68
Target
$29.18
$29.18
$17.82
$29.18 avg
$40.31
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.45M | 8.50M | 8.91M |
| Net Income | 239.2K | 243.9K | 245.4K |
| Profit Margin | 2.5% | 2.9% | 2.8% |
| EBITDA | 403.0K | 435.3K | 434.6K |
| Free Cash Flow | 313.2K | 273.2K | 249.3K |
| Rev Growth | +19.1% | +23.4% | +6.1% |
| Debt/Equity | 0.60 | 0.55 | 0.53 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |